Reimbursement Intelligence Digest — Week of July 20, 2026
### Clinical Laboratory - **LCD L40140, L40249, L40060, L40062, L40058: Molecular Testing for Solid Organ Allograft Rejection** Review documentat
Actions Required This Week
Clinical Laboratory - LCD L40140, L40249, L40060, L40062, L40058: Molecular Testing for Solid Organ Allograft Rejection Review documentation for molecular tests related to solid organ allograft rejection under each Local Coverage Determination (LCD). Action Required by: Immediate compliance review. Validate specific CPT/HCPCS codes listed in each LCD.
Sign in to read the full article
Create a free account to access the complete analysis, action recommendations, and related alert references.
Quick answers
What actions are required for Clinical Laboratory adherence?
Immediate compliance review is required for each listed LCD regarding molecular testing for solid organ allograft rejection. Validate specific CPT/HCPCS codes listed in each LCD.
What should oncology coding teams do following the FDA approvals?
Oncology coding teams need to update formularies and billing documentation to include newly approved drugs like PADCEV, RETEVMO, REVTORPYK, and VERZENIO, effective immediately from respective approval dates.
What is required of dermatology practices following new FDA approvals?
Dermatology practices should immediately update their formulary and patient eligibility documentation to reflect the approval of ustekinumab, ensuring charge capture is current.
What is the importance of CMS Transmittal R13859CP for Multi-specialty practices?
Multi-specialty practices must review and adjust billing documentation to align with the updated payment allowances for influenza vaccines for the 2026-2027 season, effective immediately.
Content summarized from publicly available federal publications including CMS, MAC contractors, and the Federal Register. CLV Intelligence is not affiliated with or endorsed by any government agency. This is not legal or medical advice.